Innate Pharma receives development milestone payment from Bristol-Myers Squibb
Opening of the Phase I/II trial of IPH2201 in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia
First patient treated in phase I/II trial with IPH2201 in ovarian cancer
Presentation of IPH4102 rationale and phase I design at the cutaneous lymphoma task force meeting of the EORTC
First half of 2015: landmark agreement with AstraZeneca and strong financial position
Fifth data and safety monitoring board meeting of the EffiKIR trial recommends continuation without modification
Presentation of IPH4102 rationale and Phase I protocol to be presented at the upcoming EORTC cutaneous lymphoma task force meeting
Upcoming investor conferences
Clearance of co-development and commercialization agreement with AstraZeneca and receipt by Innate Pharma of $250m initial payment
IPC, the comprehensive cancer center of Marseille, and Innate Pharma collaborate on translational research for novel immune checkpoint inhibitors
